Applied Genetic Technologies Corporation (AGTC) was founded by five scientific leaders in the use of viral vectors for Gene Therapy and began operations in 2001. They subsequently secured rights to a portfolio of strategically vital intellectual property in the application of Adeno-Associated Virus (AAV) to gene therapy. Since that time the Company has signed licenses to over 40 US and foreign patents, raised over $45M in venture financing from blue chip investors and has five products in active development, one of which is partnered to Genzyme Corporation.
AGTC's most recent round of financing was completed in April 2009 and was led by Interwest Partners of Menlo Park, CA. Other investors included Intersouth Partners of RTP, NC and MedImmune Ventures of Gaithersburg, MD.
Funding Rounds (5) - $78.05MUpdate
Current Team (10)Update
|Aug 29, 2016||businesslist.vardoo.com - , business list, corporation information, business profile , Applied Genetic Technologies Corporation profile|
|Feb 5, 2016||PRNewswire UK All - Gene Therapy R&D and Revenue Forecasts 2016-2026|
|Oct 3, 2015||equities.com - IPO Report: Applied Genetic Technologies (AGTC) - Equities.com - Global Financial Community|
|Mar 27, 2014||gainesville.com - Applied Genetic Technologies nets $50M in IPO|
|Mar 27, 2014||Nasdaq - APPLIED GENETIC TECHNOLOGIES CORP (AGTC) IPO|
|Aug 22, 2013||SEC - SEC FORM D|
|Nov 20, 2012||BioSpace - Applied Genetic Technologies Corporation Lands 37|
|Sep 15, 2010||BioSpace - Applied Genetics Technologies Corporation raises 1000000 in grant round|
11801 Research Drive
Alachua, FL 32615